Join the IMS Health Symposium“Bridging the real-world evidence (RWE) divide with payers and integrated deliverynetworks (IDNs): Making pharma a true collaborator in evidence”Meet the largest expert community in RWE and HEOR - now including our new colleagues who have joined us from Cegedim Strategic Data

Discover the findings from our latest research

ISPOR 20th Annual International Meeting16-20 May 2015, Philadelphia, USA

IMS Health Real-World EvidenceSolutions at ISPOR

2

Our Distinctive Approach

IMS Health takes a straightforward, credible, global approach to using real-world data(RWD) for decision making and engagement to support HQ and market-level need.

We combine the best data for client research requirements, expertise and innovation in technology andanalytics, and powerful applications tailored by need, to create and deploy evidence that enablesdecision and alignment. With foundational depth and geographic breadth we deliver insights thatenhance understanding of product efficacy, safety, cost and value to inform a new world where patientoutcomes are the currency that brings healthcare stakeholders together.

IMS Health Real-World Evidence Solutions

Real-World Data• The broadest and deepest collection of

scientifically validated, anonymous patient-level data assets

• Custom data sourcing

Technology-Enabled Analytics• Analytic tools that leverage

powerful technologies to deliverscientific and commercial insightsefficiently

Technology-EnabledAnalyticsReal-World

Data (RWD)

Services and

Engagement

IMS HEALTHREAL-WORLD

EVIDENCESOLUTIONSServices and Engagement

• Market Access & HTA• Health Economics• Outcomes Research• Pharmacoepidemiology & Drug Safety

IMS Health is excited to announce that Cegedim Strategic Data has joined our Real-World Evidence Solutions

team, boosting our RWD assets and analytical expertise and confirming our role as the partner of choice for RWE.

• 500+ million anonymous longitudinal patient datarecords in 25+ markets

• Partnerships and data sourcing capabilities toensure clients have the ‘right fact base’

• 3,000+ publications building healthcare knowledge

• Leading edge technology and analytics toenhance understanding of patient outcomes,healthcare costs, drug safety and product value

• Experts in 20+ markets with deep specialism inRWE, HTA and payer requirements to translateinsights into actions

#1 RWE Partner of Choice

ISPOR 20th Annual International Meeting, 16-20 May 2015, Philadelphia, USA 3

Vastly expanding healthcare datasets are driving new potential for real-worldinformation to tangibly improve patient outcomes – empowered by unprecedentedinnovation in connectivity, methodology and analytics.

Despite these tremendous advances, challenges remain for the successful infusion of insights derivedfrom RWD across the healthcare system, to promote cost-effectiveness, inform clinical practice anddrive efficient, confident decision making.

IMS Health is committed to the advancement of evidence-based healthcare by increasing awareness,enhancing credibility, developing platforms to leverage RWE, and supporting ongoing dialoguebetween relevant stakeholders. At the ISPOR 20th Annual International Meeting, we look forward toexploring the progress being made to harness big data in clinical practice.

An overview of our key activities at ISPOR can be found in this brochure on pages 6-7.

Welcome to IMS Health at ISPOR, Philadelphia, 2015

Members of our global Real-World Evidence Solutions team

will be on hand during ISPOR to discuss your needs in RWE

and HEOR and explain how we can help you address them.

Please come and see us at the IMS Health booth

(Nos 1308-1309) in the exhibition area to discover more

about our expertise and capabilities, which have recently

expanded with the exciting addition of Cegedim

Strategic Data.

Visit IMS Health in the exhibition area

IMS Health Symposium – Wednesday, 20 May

“Bridging the real-world evidence (RWE) divide with payers and integrated deliverynetworks (IDNs): Making pharma a true collaborator in evidence”

Every day, pharmaceutical companies are generating RWE studies with the intention of informingpayer decisions. However, while regulators are already seeing the benefits from improved safety anddrug utilization studies, payers have yet to adopt RWE as extensively. Where they do use it, theywidely restrict input from the industry.

To find out why, we leveraged direct experience supporting pharma but also engaged payers and IDNsdirectly on this topic. We conducted research on 100+ known cases of RWE use in payer decisions,held a joint symposium with the Center for Drug Safety & Effectiveness, Johns Hopkins School ofPublic Health including pharma, academic and payer participants, and conducted an RWE-specificsurvey with 70 US payers. In this symposium, we will share our learnings and explore tangibleopportunities for life sciences to accelerate RWE engagement and impact.

07:15 – 07:20 IntroductionG. Caleb Alexander, MD, MS (Chair), Co-Director andAssociate Professor, Center for Drug Safety &Effectiveness, Johns Hopkins School of Public Health,Baltimore, MD, USA

07:20 – 07:35Could pharma be the catalyst for IDNs and payers to use RWE more extensively?Marla Kessler, MBA, Vice President and RegionalLeader America, IMS Health, New York, USA

07:35 – 07:45 The IDN perspectiveJim Peters, MBA, Senior Vice President, Chief StrategicIndustry Partnerships Officer, Geisinger Health Systemand CEO, Geisinger Medical Management Corporation

07:45 – 07:55The payer perspectiveIra Klein, MD, MBA, FACP, National Medical Director,Clinical Thought Leadership, Aetna, Hartford, CT, USA

07:55 – 08:05Implications for pharma: A moderated panel discussionG. Caleb Alexander (Chair)

08:05 – 08:15 Q & A

4

Agenda

IMS Health Real-World Evidence Solutions

Proceedings from the symposium can be obtained by emailingAngelika Boucsein at Aboucsein@de.imshealth.com

Continental breakfast will be available for all symposium attendees

5ISPOR 20th Annual International Meeting, 16-20 May 2015, Philadelphia, USA

Symposium SpeakersG. Caleb Alexander, MD, MSDr. Caleb Alexander is founding Co-Director and Associate Professor, Center for Drug Safety & Effectiveness,Johns Hopkins School of Public Health, and a practicing general internist and pharmacoepidemiologist. He is internationally renowned for his work examining prescription drug utilization, focusing on population-based patterns and determinants of pharmaceutical use, clinical decision making regarding prescription drugs,and the impact of changes in regulatory and payment policy on pharmaceutical utilization. Caleb is an expert inconducting survey-based investigations and also has extensive experience analyzing secondary data sources. He has authored over 150 scientific publications, is Chair of the FDA's Peripheral and Central Nervous SystemAdvisory Committee, and is currently Principal or Co-Principal Investigator of RO1s from the AHRQ and NHLBIexamining the effect of FDA regulatory communications and DTC advertising on healthcare utilization. Calebhas served on numerous editorial boards and received multiple academic and research honors and awards.

Marla Kessler, MBAMarla Kessler is a Vice President, heads overall marketing efforts for IMS Health Real-World Evidence Solutionsand is an active leader of global RWE projects. She helps clients develop commercial strategies for products andportfolios, define evidence plans to support them, and coordinate implementation to ensure successfulexecution. Marla has 15 years strategic and business line experience gained through leadership roles at McKinsey& Co and Pfizer. During her career at IMS Health she has designed and led RWE boot camps to help clients buildcapabilities in this area across the broader organization. She has also developed thought leadership in RWE andrecently co-authored a major IMS Health benchmarking study exploring variations in RWE supply and demandacross the pharmaceutical industry’s top markets.

Jim Peters, MBAJim Peters is Senior Vice President, Chief Strategic Industry Partnerships Officer, Geisinger Health System,overseeing strategic corporate partnering initiatives and negotiations with multinational companies. He is alsoCEO of Geisinger's for-profit Medical Management Corporation and was a founder of MedMining, Geisinger’spharmaceutical R&D information services business and now the market leader in its segment. Previously, Jimwas a Principal at Updata Venture Partners, founded a successful technology services firm, and served as aSenior Consultant at Andersen Consulting in New York. He is an Adjunct Lecturer at Lehigh University, a GuestLecturer for the Wharton School, and an active Parkinson’s disease advocate. He serves on numerous fiduciaryand advisory Boards and is a Director and Executive Committee member at Ben Franklin Technology Partners,supporting Pennsylvania's technology-based economy.

Ira Klein, MD, MBA, FACPDr. Ira Klein is National Medical Director, Office of the Chief Medical Officer (CMO), Clinical Thought Leadershipat Aetna, responsible for core program development. He was previously Chief of Staff to the CMO and remainspart of the team responsible for communicating and deploying the strategic efforts of the CMO. Ira joined Aetnain 2006 as Medical Director, Northeast Region before transitioning to the National Accounts Sales and Supportgroup, involved in new benefits design, financial and clinical analytics, and evolution of oncology strategies. Hehas also served as Medical Director for Quality and Case Management at Bayshore Community Health Systemand as CMO at Elderplan, a Medicare Social HMO focused on the frail elderly. Ira is a Clinical Assistant Professor ofMedicine at the University of Medicine and Dentistry New Jersey–Robert Wood Johnson Medical School, participatesin numerous professional organizations and has received many honors for excellence in his field.

6

IMS Health Activities – 18 May18 MAY

CODE TOPIC PRESENTERS TYPE

MA1 IMPACT OF A PHARMACIST MEDICATION ADHERENCE CONSULTATION PROGRAM ON HEALTH CARE COSTS AND RISK OF HOSPITALIZATION

Wade RL, Hill JW, Akinbosoye O,Jiang Z, Mu Y, Sun K, Karkare S, Taitel MS

PodiumPresentation

MD2COVERAGE LIMITS ON BLOOD GLUCOSE TEST STRIP REIMBURSEMENT FORDIABETICS IN CANADA: UTILIZATION IMPACT FOR DIABETIC PATIENTS IN THEONTARIO PUBLIC DRUG PROGRAM (OPDP)

Bosnic N, Goodfield JM, Robertson CM, Zhang Y

PodiumPresentation

MO1 REDUCING AND QUANTIFYING OVER-FITTING IN REGRESSION MODELS Rigg J, Hankins M PodiumPresentation

PRM23 CONTRASTING COST-EFFECTIVENESS RESULTS DERIVED FROM CONTEMPORARY SETS OF ALTERNATIVE RISK EQUATIONS IN TYPE 2 DIABETES Foos V, Lamotte M, McEwan P Poster

Presentation

PRM37

IMPACT OF SINGLE RISK FACTOR CHANGES ON LONG-TERM OUTCOMES ANDCOST IN A TYPE 2 DIABETES MODELING STUDY CONTRASTING PROJECTIONSWITH UKPDS68, SWEDISH NATIONAL DIABETES REGISTRY AND THE ADVANCERISK EQUATIONS

McEwan P, Lamotte M, Foos V PosterPresentation

PRM48 COMPARATIVE LANDSCAPE ASSESSMENT OF US HEALTHCARE DATABASES FOR USE IN HEALTH ECONOMICS MODELING Wehler EA, Donga P, Munakata J Poster

Presentation

PRM49VALIDITY AND LIMITATIONS OF THE LONGITUDINAL PATIENT DATABASE FRANCEFOR USE IN PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMICSSTUDIES

Jouaville SL, Miotti H, Coffin G, Sarfati B, Meilhoc A

PosterPresentation

PRM73

CONTRASTING THE RELATIVE RISK REDUCTION OF CARDIOVASCULAR EVENTS IN THE CORE DIABETES MODEL ASSOCIATED WITH SINGLE RISK FACTORCHANGES ACROSS ALTERNATIVE RISK ENGINES: UKPDS68, UKPDS82 ANDSWEDISH NATIONAL DIABETES REGISTRY EQUATIONS

Foos V, Lamotte M, McEwan P PosterPresentation

PRM74ASSESSING THE RELATIVE CONTRIBUTION TO CHANGES IN QUALITY-ADJUSTEDLIFE EXPECTANCY ASSOCIATED WITH HBA1C, WEIGHT AND HYPOGLYCAEMIAACROSS MULTIPLE RISK EQUATIONS WITH THE CORE DIABETES MODEL (CDM)

McEwan P, Evans M, Lamotte M, Foos V

PosterPresentation

PMD26 CLINICAL AND COST OUTCOMES FROM DIFFERENT HYALURONIC ACIDTREATMENTS IN PATIENTS WITH KNEE OSTEOARTHRITIS

Dasa V, DeKoven M, Lim S, Long K,Heeckt P

PosterPresentation

PDB46 A HEALTH ECONOMIC EVALUATION OF THE EDGE STUDY USING THE IMS CORE DIABETES MODEL

McEwan P, Evans M, Foos V,Paldánius PM

PosterPresentation

PDB50THE COST-EFFECTIVENESS EVALUATION OF CANAGLIFLOZIN VERSUSDAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELYCONTROLLED ON METFORMIN MONOTHERAPY IN SPAIN

Nielsen AT, Pitcher A, Lovato E,Schubert A, Hemels M, Neslusan C,González B

PosterPresentation

PDB55THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN(SITA) AS AN ADD-ON TO METFORMIN OR METFORMIN PLUS SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN

Nielsen AT, Pitcher A, Lovato E,Schubert A, Hemels M, Neslusan C,González B

PosterPresentation

PDB98 ASSESSMENT OF A FRENCH ENDOCRINOLOGIST ELECTRONIC MEDICAL RECORDDATABASE FOR USE IN OBSERVATIONAL STUDIES

Hellard C, Jouaville SL, Pilet S,Meilhoc A

PosterPresentation

PMH59 USE OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) DRUGS INCANADA, 2010-2014 Aziz S, Gillman A, Griffiths J Poster

Presentation

PMH60 AUDIT OF IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)PRESCRIPTION FOR DEPRESSION IN CURRENT CLINICAL PRACTICE WITHIN THEHEALTH IMPROVEMENT NETWORK (THIN) UK PRIMARY CARE DATABASE

O'Leary CJ, Nasser A, Myland M,Waples S, Ansell D

PosterPresentation

IMS Health Real-World Evidence Solutions

20 MAY

7

IMS Health Activities – 19 & 20 May

ISPOR 20th Annual International Meeting, 16-20 May 2015, Philadelphia, USA

19 MAY

CODE TOPIC PRESENTERS TYPE

PCV78THE COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE COMPARED WITHEDOXABAN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN THE UK

Jugrin AV, Ustyugova AV, Lamotte M, Sunderland TJ

PosterPresentation

PMS88 ANALYSIS OF ETANERCEPT TREATMENT PATTERNS AND REIMBURSEMENT GAPSIN PATIENTS WHEN TRANSITIONING FROM PRIVATE TO PUBLIC DRUG PLANS

Millson B, Poulin-Costello M, Garces K

PosterPresentation

PSS14 COST OF ILLNESS, DIAGNOSIS AND TREATMENT PATTERNS FOR DIABETICMACULAR EDEMA ACROSS 13 COUNTRIES

McLeod E, Lovato E, Wittrup-Jensen KU, Muston DR

PosterPresentation

PUK8 USE OF A FRENCH CLAIMS DATABASE TO ESTIMATE REAL-WORLD TREATMENTCOSTS OF BENIGN PROSTATIC HYPERPLASIA Jouaville SL, DiNicola S, Boutmy E Poster

Presentation

PCN52COSTS OF TREATING SKELETAL-RELATED EVENTS AMONG PROSTATE CANCERPATIENTS WITH BONE METASTASES IN A COMMERCIAL INSURED POPULATION IN THE US

Zhong Y, Yao J, Donga P, Bilir SP,Valderrama A

PosterPresentation

PCN74

COST-EFFECTIVENESS OF RADIUM-223 DICHLORIDE (RADIUM-223) IN ALSYMPCA: A COST-EFFECTIVENESS ANALYSIS OF RADIUM-223+BEST STANDARD OF CARE (BSOC) COMPARED WITH PLACEBO+BSOC IN TREATMENTOF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATICBONE METASTASES IN CANADA

Henricks P, Cislo P, Zhan L, Beaudet A, Grabbi E, Lloyd A,Fleshner N, Chin W

PosterPresentation

PCN137METASTATIC MELANOMA PATIENT CHARACTERISTICS AS A DETERMININGFACTOR FOR BRAF GENE MUTATION TESTING AND TREATMENT IN CANADA – A RETROSPECTIVE COHORT STUDY

Djokic S, Lapierre M PosterPresentation

PGI36 SPENDING ON HEPATITIS C ANTIVIRALS IN THE UNITED STATES, 2008-2014 Suda KJ, Hunkler RJ, Matusiak L,Vermeulen L, Schumock G

PosterPresentation

BRIDGING THE REAL-WORLD EVIDENCE (RWE) DIVIDE WITH PAYERS ANDINTEGRATED DELIVERY NETWORKS (IDNS): MAKING PHARMA A TRUECOLLABORATOR IN EVIDENCE

Alexander GC, Kessler M, Peters J,Klein I

IMS HealthSymposium

PHS159 THE BURDEN OF GOUT IN A CANADIAN PRIMARY CARE POPULATIONWilliams DM, Cowan C, Gendron A,Goodfield J, Oraichi D, Fischer A,Borrelli R, Liu N, Dziarmaga A

PosterPresentation

PSY68DOSING PATTERN ANALYSIS FOR BIOLOGICS IN THE TREATMENT OF PSORIASISIN CANADA: INDICATION-SPECIFIC INFORMATION RETRIEVED FROMADMINISTRATIVE CLAIMS DATABASE

Gregory V, Liu N, Robertson C,Gerega S, Barbeau M, Budry L

PosterPresentation

PSY74 CANADIAN RETROSPECTIVE CLAIMS DATA ANALYSIS OF BIOLOGICS SWITCHINGAND RETENTION PATTERNS IN PSORIASIS PATIENTS

Millson B, Poulin-Costello M, Garces K

PosterPresentation

©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

ORB01126

IMS Health Real-World Evidence Solutionsis based in 20 countries worldwide with regional headquarters in

RWEinfo@imshealth.comwww.imshealth.com/rwe

Europe210 Pentonville RoadLondon N1 9JYUnited KingdomTel: +44 (0) 20 3075 4800

The Americas8280 Willow OaksCorporate DriveSuite 775Fairfax Virginia 22031USATel: +1 (703) 992 1025

Latin AmericaInsurgentes Sur # 2375 5th FloorCol. TizapanMéxico D.F.- C.P. 01090México Tel: +52 55 5089 5205

Asia Pacific & Japan8 Cross Street #21-01/02/03Singapore 048424SingaporeTel: +65 6412 7365

Toranomon Towers Office4-1-28 ToranomonMinato-ku Tokyo 150-0001JapanTel: +81 3 5425 9541

IMS Health Real-World Evidence Solutions Bibliography

Our research expertise and therapy area knowledge are captured inmore than 3,000 publications, spanning virtually all therapy areasand projects completed in over 50 countries worldwide.

Pick up a copy of the latest IMS Health Real-World Evidence Solutions Bibliographyof published papers and presentations (2012-2015) incorporating publications fromCegedim Strategic Data, now part of IMS Health, from our booth at ISPOR or visitwww.imsrwebibliography.com to explore our database online.